<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1856">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05137002</url>
  </required_header>
  <id_info>
    <org_study_id>CIN-107-124</org_study_id>
    <nct_id>NCT05137002</nct_id>
  </id_info>
  <brief_title>A Study of CIN-107 in Patients With Uncontrolled Hypertension Receiving 1 Antihypertensive Agent</brief_title>
  <acronym>HALO</acronym>
  <official_title>A Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Multiple Dose Strengths of CIN-107 as Compared to Placebo After 8 Weeks of Treatment in Patients With Uncontrolled Hypertension Receiving 1 Antihypertensive Agent</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CinCor Pharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CinRx</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>CinCor Pharma, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2, randomized, multicenter study to evaluate the efficacy and safety of&#xD;
      multiple dose strengths of CIN-107 in the treatment of patients with uncontrolled&#xD;
      hypertension who are currently taking 1 anti-hypertensive medication&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in mean seated systolic BP (SBP)</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in mean seated diastolic BP (DBP)</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in 24-hour urine aldosterone and serum aldosterone</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients achieving a mean seated SBP &lt;130 mmHg</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">212</enrollment>
  <condition>Uncontrolled Hypertension</condition>
  <arm_group>
    <arm_group_label>CIN-107 0.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Remain on background (single drug) hypersensitive regimen for 8 weeks. After 8 weeks, patient may be up-titrated to a higher dose of CIN-107 and/or may come off their background anti-hypertensive medication for 4 weeks depending on BP control</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CIN-107 1 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Remain on background (single drug) hypersensitive regimen for 8 weeks. After 8 weeks, patient may be up-titrated to a higher dose of CIN-107 and/or may come off their background anti-hypertensive medication for 4 weeks depending on BP control</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CIN-107 2 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Remain on background (single drug) hypersensitive regimen for 8 weeks. After 8 weeks, patient may be up-titrated to a higher dose of CIN-107 and/or may come off their background anti-hypertensive medication for 4 weeks depending on BP control</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Remain on background (single drug) hypersensitive regimen for 8 weeks. After 8 weeks, patient may be up-titrated to a higher dose of CIN-107 and/or may come off their background anti-hypertensive medication for 4 weeks depending on BP control</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CIN-107</intervention_name>
    <description>CIN-107 tablets by mouth once daily</description>
    <arm_group_label>CIN-107 0.5 mg</arm_group_label>
    <arm_group_label>CIN-107 1 mg</arm_group_label>
    <arm_group_label>CIN-107 2 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablets by mouth once daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Is on a stable regimen of a single background antihypertensive agent for at least 8&#xD;
             weeks and a second antihypertensive agent is warranted at the time of screening;&#xD;
&#xD;
          -  Has a mean seated systolic blood pressure (SBP) ≥ 140 mmHG;&#xD;
&#xD;
          -  Demonstrates they are able to be adherent to the study drug and their&#xD;
             anti-hypertensive medication during a run-in period&#xD;
&#xD;
          -  If taking SGLT2 inhibitor, the regimen must be stable for at least 8 weeks prior to&#xD;
             randomization; and&#xD;
&#xD;
          -  Agrees to comply with the contraception and reproduction restrictions of the study;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has a mean seated systolic blood pressure (SBP) ≥180 mmHG;&#xD;
&#xD;
          -  Has a body mass index (BMI) &gt;50 kg/m2;&#xD;
&#xD;
          -  Is using alpha or beta blockers for any primary indication other than systemic&#xD;
             hypertension (eg, migraine headache);&#xD;
&#xD;
          -  Is not willing or not able to discontinue an MRA or potassium sparing diuretic as part&#xD;
             of an existing antihypertensive regimen;&#xD;
&#xD;
          -  Has documented estimated eGFR &lt;30 mL/min/1.73m2;&#xD;
&#xD;
          -  Has known and documented New York Heart Association stage III or IV chronic heart&#xD;
             failure;&#xD;
&#xD;
          -  Has had a stroke, transient ischemic attack, hypertensive encephalopathy, acute&#xD;
             coronary syndrome, or hospitalization for heart failure within 6 months before&#xD;
             screening;&#xD;
&#xD;
          -  Major cardiac surgery within 6 months before Screening;&#xD;
&#xD;
          -  Has chronic permanent atrial fibrillation;&#xD;
&#xD;
          -  Has uncontrolled diabetes with glycosylated hemoglobin &gt;10% at Screening;&#xD;
&#xD;
          -  Has planned dialysis or kidney transplantation planned during the course of the study;&#xD;
&#xD;
          -  Prior solid organ transplant and/or cell transplants;&#xD;
&#xD;
          -  Sodium &lt;130 mEq/L;&#xD;
&#xD;
          -  Potassium &lt;3.5 mEq/L;&#xD;
&#xD;
          -  Potassium &gt;5 mEq/L;&#xD;
&#xD;
          -  Is positive for HIV antibody, hepatitis C virus RNA, or hepatitis B surface antigen;&#xD;
&#xD;
          -  Has typical consumption of ≥14 alcoholic drinks weekly;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yuan-Di Halvorsen</last_name>
    <phone>513-800-2585</phone>
    <email>yhalvorsen@cincor.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>CinCor Site 6</name>
      <address>
        <city>Lincoln</city>
        <state>California</state>
        <zip>95648</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wayne</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CinCor Site 7</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Farris</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 16, 2021</study_first_submitted>
  <study_first_submitted_qc>November 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 30, 2021</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

